Abstract: The present document relates to pyrazolopyrimidine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the pyrazolopyrimidine compounds, or a tautomeric form and/or salt thereof, are of Formula I: Formula I wherein R1 to R4 are as defined herein.

Abstract: The present invention provides novel amino chromen-2-one compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.

Abstract: Disclosed are compounds according to Formula (1) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.

Abstract: Disclosed are compounds according to Formula (1) and Formula (2) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.

Abstract: Disclosed are compounds according to Formula (1) which inhibit LONP1, and pharmaceutical compositions comprising compounds of the disclosure. Compounds and pharmaceutical compositions of the disclosure may be useful for the treatment of diseases and disorders associated with LONP1, including oncologic diseases and disorders, such as cancer, and diseases and disorders related to mitochondrial dysfunction, such as neurodegenerative disorders, metabolic disorders, and diseases associated with the aging process. The disclosure also relates to methods of using such compounds and compositions for the treatment of such diseases and disorders.

Abstract: The present document relates to tetrahydropyridazine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For example, the tetrahydropyridazine compounds, or a tautomeric form and/or salt thereof, are of Formula I, wherein R1 to R4, X1, and a are as defined herein.

Abstract: The present invention provides novel isoquinolinone and quinolinone compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.

Abstract: The present invention provides novel hydroxy and alkoxy coumarin compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.

Abstract: A method, apparatus, system, or computer-readable medium for performing object-level encryption and key rotations is disclosed. A service platform may store data items organized into one or more asset clusters. A first content encryption key may be set as the active encryption key for an asset cluster. The active encryption key may be encrypted using the master encryption key. A first subset of data items may be encrypted using the active encryption key (e.g., the first content encryption key). After the number of data items encrypted using the active encryption key satisfies a threshold value, the first content encryption key may be set as an inactive encryption key and a second content encryption key may be set as the new active encryption key for the asset cluster. A second subset of the plurality of data items may be encrypted using the active encryption key (e.g., the second content encryption key).

Abstract: A heat exchanger tube with outside diameter less than or equal to ten (10) inches and inside diameter greater than or equal to one-tenth (0.1) inches, comprising an inlet and an outlet; the heat exchanger tube enclosing and at least partly in contact with flow of a first fluid with the tube inner surface, separated from a second fluid at least partially in contact with the heat exchanger tube outer surface; one or a plurality of ridges disposed on the inner surface of the heat exchanger tube wall; a ridge having a height measured from the inner heat exchanger wall surface of less than or equal to one (1.0) millimeter.

Abstract: A method, apparatus, system, or computer-readable medium for performing object-level encryption and key rotations is disclosed. A service platform may store data items organized into one or more asset clusters. A first content encryption key may be set as the active encryption key for an asset cluster. The active encryption key may be encrypted using the master encryption key. A first subset of data items may be encrypted using the active encryption key (e.g., the first content encryption key). After the number of data items encrypted using the active encryption key satisfies a threshold value, the first content encryption key may be set as an inactive encryption key and a second content encryption key may be set as the new active encryption key for the asset cluster. A second subset of the plurality of data items may be encrypted using the active encryption key (e.g., the second content encryption key).

Abstract: In some implementations, a data migration device may querying a relational data store for a plurality of metadata items. Accordingly, for each metadata item, the data migration device may transmit, to an application programming interface (API), a request for the metadata item, and receive, from the relational data store via the API, the metadata item. Furthermore, for each metadata item, the data migration device may execute a transformation on the metadata item to generate an adapted metadata item for a non-relational data store and transmit, to the API, a request to store the adapted metadata item in the non-relational data store.

Abstract: A protective packaging system comprises a pouch, and a receptacle for insertion into the pouch. The receptacle comprises a base surface and a perimeter structure extending from the base surface around at least half of the perimeter of the base surface.

Abstract: The system can include a diffuser disposed at a rear of a vehicle. A side of the diffuser can be positioned to face the earth. The system can include an actuator coupled with the diffuser and configured to deploy the diffuser to adjust drag on the vehicle. The system can include a sensor configured to detect an obstacle. The system can include one or more processors that are in communication with the sensor and the actuator. The one or more processors can be configured to identify a mode of operation of the vehicle. The one or more processors can be configured to determine, based on input from the sensor and the mode of operation, a position to which to move the diffuser. The one or more processors can be configured to transmit a command to the actuator to move the diffuser to the position.

Abstract: Provided herein are P2X3 modulators and methods of utilizing P2X3 modulators in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Abstract: A passenger includes at least one seat component including a first material and at least one additive manufactured component including a second material, the at least one additive manufactured component including a plurality of zones. The at least one additive manufactured component is attached to the at least one seat component. The at least one additive manufactured component includes a lattice structure. Each of the plurality of zones have different physical properties.

Abstract: Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (?)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethy lamine, (R)-(?)-2-amino-3-methyl-1-butanol, (?)-cinchonidine, (?)-spartein, (R)-1-naphthylethy lamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and(1R,2S)-(+)-cis-1-amino-2-indanol.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

Abstract: A privacy panel assembly for a passenger seat includes a vertically extending panel attached to a lateral surface of the passenger seat such that the vertically extending panel includes a forward edge and an aft edge and at least one sliding mechanism attached to an interior surface of the vertically extending panel. The vertically extending panel includes a stowed configuration and a deployed configuration. In the stowed configuration, the aft edge of the vertically extending panel is disposed on an aft side of a rear surface of a seatback of the passenger seat. In the deployed configuration, the aft edge of the vertically extending panel is approximately aligned with a seating surface of the seatback on a forward side of the passenger seat.